PTCT
HEALTHCAREPTC Therapeutics Inc
$66.57+1.53 (+2.35%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PTCT Today?
No stock-specific AI insight has been generated for PTCT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$43.17$87.50
$66.57
Fundamentals
Market Cap$5.3B
P/E Ratio7.5
EPS$8.58
Dividend Yield—
Dividend / Share—
ROE-77.4%
Profit Margin0.4%
Debt / Equity—
Trading
Volume638K
Avg Volume (10D)—
Shares Outstanding82.9M
PTCT News
20 articles- PTC Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Sector Update: Healthcare Stocks Lower Late AfternoonYahoo Finance·May 8, 2026
- PTC Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 7, 2026
- PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Global RNA Targeting Small Molecule Drug Discovery Market Size/Share Worth USD 17.6 Billion by 2035 at a 22.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)Yahoo Finance·May 6, 2026
- Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPSYahoo Finance·May 6, 2026
- Assessing PTC Therapeutics (PTCT) Valuation After Encouraging New Huntington’s Disease DataYahoo Finance·May 5, 2026
- How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And Franchise PressuresYahoo Finance·May 5, 2026
- Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseYahoo Finance·May 4, 2026
- PTC Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·May 4, 2026
- Ardena Strengthens Executive Team to Drive its Next Phase of GrowthYahoo Finance·May 4, 2026
- PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial ResultsYahoo Finance·May 2, 2026
- PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis MilestoneYahoo Finance·Apr 30, 2026
- PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 30, 2026
- PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing SignalsMarketbeat·Apr 29, 2026
- PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of VotoplamYahoo Finance·Apr 28, 2026
- PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyYahoo Finance·Apr 28, 2026
- PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026Yahoo Finance·Apr 22, 2026
All 20 articles loaded
Price Data
Open$65.98
Previous Close$65.04
Day High$66.83
Day Low$65.44
52 Week High$87.50
52 Week Low$43.17
52-Week Range
$43.17$87.50
$66.57
Fundamentals
Market Cap$5.3B
P/E Ratio7.5
EPS$8.58
Dividend Yield—
Dividend / Share—
ROE-77.4%
Profit Margin0.4%
Debt / Equity—
Trading
Volume638K
Avg Volume (10D)—
Shares Outstanding82.9M
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—